Clinical trials: Neoplasms，Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70…
- Trial name
- NCT00137800
- Testing
- OSI-774 (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Background: The current standard of care for advanced lung cancer and cancers of the thymus consists primarily of chemotherapy treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
- Trial name
- NCT01306045
- Testing
- AZD6244, MK-2206, Lapatinib
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer, Lung Cancer
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, NSCLC
- Trial name
- NCT01222572
- Testing
- Stereotactic boost, Conventional RT, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms，Non-Small Cell Lung Cancer
Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer
The purpose of this study is to assess the pharmacokinetics，safety and tolerability of Hemay020 and to determine the recommended dose for future Phase II study as well as to obtain preliminary information on the efficacy of…
- Trial name
- NCT02467569
- Testing
- Hemay020
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Non-small Cell Lung Cancer, Urothelial Cancer
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
This is a Phase 1b/2, open label, multicenter, safety and clinical activity study of avelumab in combination with chemotherapy as first-line treatment of adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT03317496
- Testing
- Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in combination with gemcitabine / cisplatin., Avelumab 1200 mg in combination with pemetrexed/carboplatin
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer.
- Trial name
- NCT00265603
- Testing
- Extracorporeal Photochemotherapy With Transimmunization
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Atlantic Health System
Advanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
This is a small phase I study with dose escalation and dose expansion cohorts. The former cohort will need up to 12 subjects with advanced solid tumor to define feasibility and recommended phase 2 dose (RP2D); the latter up to 10…
- Trial name
- NCT03217669
- Testing
- Epacadostat, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Chao Huang
Non Small Cell Lung Cancer
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759
This is a multi-center, open-label, dose escalation and phase I/II study, consisting of dose escalation in Part A and phase II study in Part B.
- Trial name
- NCT03360929
- Testing
- AZD3759
- Where
- 4 sites in China
- Volunteers
- 15 people
- Sponsor
- LYZZ Alpha Holding Ltd
Advanced Non-Small Cell Lung Cancer (NSCLC)
Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial
The goal of this clinical trial is to evaluate whether individualized sequencing of immunotherapy and chemotherapy based on immune dynamics can improve treatment outcomes in adults with advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07190027
- Testing
- Arm 1： Standard Synchronous Group, Arm 2：Fixed Delay Group, Arm 3： Individualized Delay Group
- Volunteers
- 246 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
NSCLC
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation
The primary objective of this study is to evaluate the safety and tolerability of TY-9591, with dose-escalation stage and dose-expansion stage.
- Trial name
- NCT04204473
- Testing
- TY-9591(10mg,40mg) qd. po
- Where
- China
- Volunteers
- 105 people
- Sponsor
- TYK Medicines, Inc
Squamous NSCLC
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
The study consists of two parts: Part I is a randomized, double-blind, multicenter, parallel-controlled phase II clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus…
- Trial name
- NCT07318883
- Testing
- HLX07, Serplulimab, Pembrolizumab
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Shanghai Henlius Biotech
Non-small Cell Lung Cancer Metastatic
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per cycle) until disease progression or…
- Trial name
- NCT03656094
- Testing
- Pembrolizumab plus chemotherapy
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Lung Cancer
Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00616031
- Testing
- carboplatin, nitroglycerin, paclitaxel
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Kyoto University
Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than…
- Conditions
- Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT04892953
- Testing
- Carboplatin, Durvalumab, Gemcitabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab…
- Trial name
- MountainTAP-29 (NCT07063745)
- Testing
- BMS-986504, Pembrolizumab, Cisplatin
- Where
- 321 sites in United States, Argentina and 32 more
- Volunteers
- 590 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer
This is a prospective randomized clinical trial with the study cohort comprised of all male and female patients over the age of 21 presenting to the study site for evaluation of lung cancer.
- Trial name
- NCT00970645
- Testing
- Mediastinoscopy/thoracoscopy, EBUS/EUS
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer
Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study
Current guidelines in non-small cell lung cancer recommend genomic assessment for mutations in EGFR and BRAF, gene rearrangements in ALK and ROS1, and resistance mutations such as T790M upon progression during EGFR inhibitor…
- Trial name
- VALUE (NCT03576937)
- Testing
- GUARDANT360
- Where
- 6 sites in Canada
- Volunteers
- 207 people
- Sponsor
- University Health Network, Toronto
Non Small Cell Lung Cancer
Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations
This study is a prospective trial of Alimta (pemetrexed) versus IRESSA (gefitinib) among epidermal growth factor receptor wild-type Non-Small Cell Lung Cancer (NSCLC) patients in a 2nd line setting.
- Trial name
- NCT00891579
- Testing
- Pemetrexed (Alimta), Gefitinib (IRESSA)
- Where
- 7 sites in China
- Volunteers
- 161 people
- Sponsor
- Chinese Society of Lung Cancer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.